DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Park JH, Palomba ML, Batlevi C. et al.
A phase I first‐in‐human clinical trial of CD19‐targeted 19‐28z/4‐1BBL “armored” CAR T cells in patients with relapsed or refractory NHL and CLL including Richter’s transformation.
Blood 2018;
132: 224
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.